Received: from westeu11-emailsignatures-cloud.codetwo.com (20.93.157.195) by ZR1PEPF0000E6BC.mail.protection.outlook.com (10.167.241.75) with Microsoft SMTP Server (version=TLS1_2, cipher=TLS_ECDHE_RSA_WITH_AES_256_GCM_SHA384) id 15.21.472.14 via Frontend Transport; Wed, 30 Sep 2026 12:06:20 +0000 Received: from ZR1PEPF0000E6BC.eurprd07.prod.outlook.com (2603:10a6:102:1fd:cafe::5) by PAZP264CA0065.outlook.office365.com (2603:10a6:102:1fd::12) with Microsoft SMTP Server (version=TLS1_3, cipher=TLS_AES_256_GCM_SHA384) id 15.21.472.16 via Frontend Transport; Wed, 30 Sep 2026 12:06:21 +0000 Received: from DB3PR08CU002.outbound.protection.outlook.com (40.93.64.86) by westeu11-emailsignatures-cloud.codetwo.com with CodeTwo SMTP Server (TLS12) via SMTP; Wed, 30 Sep 2026 12:06:19 +0000 Received: from GV2PR02MB11921.eurprd02.prod.outlook.com ([fe80::9f24:8c81:10e8:7104]) by GV2PR02MB11921.eurprd02.prod.outlook.com ([fe80::9f24:8c81:10e8:7104%5]) with mapi id 15.21.0451.022; Wed, 30 Sep 2026 12:06:18 +0000 Received: from GV2PR02MB11921.eurprd02.prod.outlook.com (2603:10a6:150:351::5) by DBAPR02MB6165.eurprd02.prod.outlook.com (2603:10a6:10:18e::8) with Microsoft SMTP Server (version=TLS1_2, cipher=TLS_ECDHE_RSA_WITH_AES_256_GCM_SHA384) id 15.21.472.15; Wed, 30 Sep 2026 12:06:18 +0000 Received: from AS4PR02MB8286.eurprd02.prod.outlook.com (2603:10a6:20b:506::21) by VI1PR02MB5024.eurprd02.prod.outlook.com with HTTPS; Wed, 30 Sep 2026 12:06:26 +0000 Received: from PAZP264CA0065.FRAP264.PROD.OUTLOOK.COM (2603:10a6:102:1fd::12) by AS4PR02MB8286.eurprd02.prod.outlook.com (2603:10a6:20b:506::21) with Microsoft SMTP Server (version=TLS1_2, cipher=TLS_ECDHE_RSA_WITH_AES_256_GCM_SHA384) id 15.21.451.23; Wed, 30 Sep 2026 12:06:21 +0000 From: "Kommunikatsioon - RA" To: =?utf-8?Q?K=C3=A4rolin_Jenas_-_RA?= References: In-Reply-To: Subject: Ed: Apteegiaparaadid Date: Wed, 30 Sep 2026 15:06:18 +0300 Message-ID: MIME-Version: 1.0 Content-Type: multipart/related; boundary="----=_NextPart_000_0599_01DD5642.686FA380" X-Mailer: Microsoft Outlook 16.0 Thread-Index: AQJNrtJkb3N6ZX0J4VTaJRaxHLXQSwI1Pi5TAhbTakA= Authentication-Results: mx.microsoft.com 1; spf=pass (sender IP is 20.93.157.195) smtp.mailfrom=ravimiamet.ee; dkim=none (message not signed) header.d=none;dmarc=pass action=none header.from=ravimiamet.ee; x-ms-traffictypediagnostic: GV2PR02MB11921:EE_|DBAPR02MB6165:EE_|ZR1PEPF0000E6BC:EE_|AS4PR02MB8286:EE_|VI1PR02MB5024:EE_ X-MS-Office365-Filtering-Correlation-Id: 54911d8a-ffe8-4099-b522-08df1eeb3da2 X-MS-Exchange-Transport-CrossTenantHeadersStamped: AS4PR02MB8286 X-MS-Exchange-Transport-CrossTenantHeadersStamped: DBAPR02MB6165 X-MS-Exchange-Organization-ExpirationStartTime: 30 Sep 2026 12:06:21.0120 (UTC) X-MS-Exchange-Organization-ExpirationStartTimeReason: OriginalSubmit X-MS-Exchange-Organization-ExpirationInterval: 1:00:00:00.0000000 X-MS-Exchange-Organization-ExpirationIntervalReason: OriginalSubmit X-MS-Exchange-Organization-Network-Message-Id: 54911d8a-ffe8-4099-b522-08df1eeb3da2 X-EOPAttributedMessage: 0 X-MS-Exchange-Organization-MessageDirectionality: Originating X-MS-PublicTrafficType: Email X-MS-Exchange-Organization-AuthSource: GV2PR02MB11921.eurprd02.prod.outlook.com X-MS-Exchange-Organization-AuthAs: Internal X-MS-Exchange-AtpMessageProperties: SA X-MS-Exchange-Organization-SCL: 1 X-Microsoft-Antispam: BCL:0;ARA:13230040|366016|82310400026|31052699007|39142699007|35042699022|6049299003|23010399003|18002099003|22082099003|55112099003|4143699003|10067099003|56012099006|11063799006|8096899003|41050700001; X-Forefront-Antispam-Report: CIP:20.93.157.195;CTRY:NL;LANG:et;SCL:1;SRV:;IPV:NLI;SFV:NSPM;H:westeu11-emailsignatures-cloud.codetwo.com;PTR:westeu11-emailsignatures-cloud.codetwo.com;CAT:NONE;SFS:(13230040)(366016)(82310400026)(31052699007)(39142699007)(35042699022)(6049299003)(23010399003)(18002099003)(22082099003)(55112099003)(4143699003)(10067099003)(56012099006)(11063799006)(8096899003)(41050700001);DIR:INT; X-MS-Exchange-CrossTenant-OriginalArrivalTime: 30 Sep 2026 12:06:20.9095 (UTC) X-MS-Exchange-CrossTenant-Network-Message-Id: 54911d8a-ffe8-4099-b522-08df1eeb3da2 X-MS-Exchange-CrossTenant-Id: 8fe098d2-428d-4bd4-9803-7195fe96f0e2 X-MS-Exchange-CrossTenant-AuthSource: GV2PR02MB11921.eurprd02.prod.outlook.com X-MS-Exchange-CrossTenant-AuthAs: Internal X-MS-Exchange-CrossTenant-FromEntityHeader: HybridOnPrem X-MS-Exchange-Transport-EndToEndLatency: 00:00:05.9694297 X-MS-Exchange-Processed-By-BccFoldering: 15.21.0451.014 X-MS-Exchange-ExternalInOutlookResult: NotEnabled X-Microsoft-Antispam-Mailbox-Delivery: ucf:0;jmr:0;auth:0;dest:I;ENG:(910005)(944506478)(944626604)(920097)(425001)(930201)(20251009189)(140003); X-Microsoft-Antispam-Message-Info: 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 x-ms-exchange-organization-originalclientipaddress: 87.119.177.68 x-ms-exchange-organization-originalserveripaddress: 10.167.241.75 Content-Language: en-us received-spf: Pass (protection.outlook.com: domain of ravimiamet.ee designates 20.93.157.195 as permitted sender) receiver=protection.outlook.com; client-ip=20.93.157.195; helo=westeu11-emailsignatures-cloud.codetwo.com; pr=C X-OlkEid: 00000000354180B9476080459B05E1BF834B446F070034AD76187591974DBF6C4F76951C873A01000200000000002495DA25D80D98438130990BFAFE78050000000007620000701E9F5783A2074383AF4B4CED3B3122 X-MS-Has-Attach: yes X-MS-TNEF-Correlator: acceptlanguage: et-EE, en-US X-Microsoft-Antispam-Untrusted: BCL:0;ARA:13230040|366016|31052699007|39142699007|6049299003|23010399003|55112099003|18002099003|22082099003|10067099003|4143699003|56012099006|11063799006|8096899003|41050700001; X-Microsoft-Antispam-Message-Info-Original: AI9A2Eb/tQ6Qw1xBNLA6lQlRJ0HIQ+8XBxHgkr9Cbhn47lDau+Eiykf41nDCVGS0UFtMt8SxDAFLYFgR3Nq+IBgoaqis1y9ToZaOD/UUNASPOSWrot2L2ycioqTCilrLjcW9rIqd1631M2i0jzJiur5ACotjldv9GPBPPdxaQe3Yr62FgHVD16YIrEL0gj2hIiVoWqwAtzMmwUVQEvqA4T2eEiN7y6K16JMuyCkLI9dsYQz42TJs128nIt5UDgq1tJdQ9WMn6fveaycrohIhLYOuy4BuArcTlhvowdlY92amnG66DAzY8P8gXpgBPh1JVI1b9HSE4RHUGPL2Znj4dz7Yesw11EQ1kwS4YU3et4l/+96vaJjyhKY6P6uDhXM6v8h4zk3fYtPuef8M+bBWpbApUlgSNHxQ0cu+RcTh3RQ/79vBM+jjeA86NtSPj+NHlyuvWUaox9jhgkmC75wgcnWOTS3aDib0dhq0HoZSAVkFagJ+k8MeQf5BTfCaFfwqvX7cytW+n3AxAosIdXI4mXkDXqhn3CPUlWhh/kuGnpIAcQWL/BzSJtn7Fsz7Ctw4CvEWP8BeNvrRqGFqCWfOBko9U2Y2Ixx86gZpF+KSinEDFtY2uyFN314eNNp4ZOCD3gGz7sQBqGV4yI4s2Ht2y8IIxirmbN7IYpE/MRwdpy7yALu8NA4xAuVNcHFdQH2d X-Forefront-Antispam-Report-Untrusted: CIP:255.255.255.255;CTRY:;LANG:et;SCL:1;SRV:;IPV:NLI;SFV:NSPM;H:GV2PR02MB11921.eurprd02.prod.outlook.com;PTR:;CAT:NONE;SFS:(13230040)(366016)(31052699007)(39142699007)(6049299003)(23010399003)(55112099003)(18002099003)(22082099003)(10067099003)(4143699003)(56012099006)(11063799006)(8096899003)(41050700001);DIR:INT; X-MS-Exchange-Transport-CrossTenantHeadersStripped: ZR1PEPF0000E6BC.eurprd07.prod.outlook.com X-MS-Office365-Filtering-Correlation-Id-Prvs: 46b851dd-5de8-43b5-6285-08df1eeb3c53 X-Exchange-RoutingPolicyChecked: hO6T1yjRew2pb+TlDHJaa3s9LPrmU/VlI3nVQBfVw+MjG6Ue0DWhh+oumV5I9iRDpKQizcfUWUyjpsIjCeN388PI/TPvjMY8cFvAZ/Owgg4s3dh9uxJ/cvjuF5nlMw8yr67Nf5BxTUCn0Dtv7SA+rHnXmSoxyqidUTRvAuRWGfmDxaUoi2B/gvEVmiNJEyjOQwuLNC+kmWFuH9oeZc7+gm+4gvPKgW91zpOb/zBuWotWApjR1EyzOi5p+cGDfjQvbtSRmr5MM0NxASp6aCytX4dBXQDvrExBKt+wD5dWkfSmtY5RSxf0wv1tvw1/cgThnp3mzboRjDd7iggeJNb8nA== msip_labels: MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_Enabled=True;MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_SiteId=8fe098d2-428d-4bd4-9803-7195fe96f0e2;MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_SetDate=2026-09-30T12:06:18.036Z;MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_Name=All Employees (unrestricted);MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_ContentBits=1;MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_Method=Standard; authentication-results-original: mx.microsoft.com 1; dkim=none (message not signed) header.d=none;dmarc=none action=none header.from=ravimiamet.ee; X-OrganizationHeadersPreserved: DBAPR02MB6165.eurprd02.prod.outlook.com X-CodeTwo-MessageID: 1179b2f9-0f08-4490-9720-3af5091b8572.20260930120619@westeu11-emailsignatures-cloud.codetwo.com X-CodeTwoProcessed: true X-MS-Exchange-Organization-AuthMechanism: 04 X-CrossPremisesHeadersPromoted: ZR1PEPF0000E6BC.eurprd07.prod.outlook.com X-CrossPremisesHeadersFiltered: ZR1PEPF0000E6BC.eurprd07.prod.outlook.com X-OriginatorOrg: m1wmgpm3xrpm87txzdfw82by7.smtp.codetwo.online X-MS-Exchange-CrossTenant-OriginalAttributedTenantConnectingIp: TenantId=8fe098d2-428d-4bd4-9803-7195fe96f0e2;Ip=[20.93.157.195];Helo=[westeu11-emailsignatures-cloud.codetwo.com] This is a multipart message in MIME format. ------=_NextPart_000_0599_01DD5642.686FA380 Content-Type: multipart/alternative; boundary="----=_NextPart_001_059A_01DD5642.686FCA90" ------=_NextPart_001_059A_01DD5642.686FCA90 Content-Type: text/plain; charset="utf-8" Content-Transfer-Encoding: 8bit Saatja: Angelina Lon > Saadetud: esmaspäev, 28. september 2026 15:42 Adressaat: Kommunikatsioon - RA > Teema: Apteegiaparaadid Tähelepanu! Tegemist on välisvõrgust saabunud kirjaga. Tundmatu saatja korral palume linke ja faile mitte avada. Tere! Kirjutan Geeniuses lugu apteegiautomaatidest, mida riik kavandab. Soovin täpsustada, kuidas hakatakse automaatides tagama ravimiohutus, nõustamine ja süsteemi töökindlus. Palun vastake järgmistele küsimustele. Kuidas näeks ravimi ostmine apteegiautomaadist samm-sammult välja? Millal peab inimene end tuvastama ja millal ühendatakse ta proviisori või farmatseudiga? Kas inimese tuvastamine ja videonõustamine on kohustuslik ka tavalise käsimüügiravimi, näiteks valuvaigisti või nohurohu ostmisel? Milliseid andmeid näeb apteeker automaati kasutava inimese kohta? Kas apteeker näeb üksnes valitud retsepti või ka inimese teisi retsepte ja varasemaid ravimioste? Kas üks apteeker võib samal ajal teenindada mitut eri kohtades asuvat automaati? Kas kehtestatakse maksimaalne automaatide või klientide arv, mida üks apteeker korraga teenindada võib? Kas automaadist võib kavandatavate reeglite järgi väljastada narkootilisi ja psühhotroopseid ravimeid? Kui jah, siis kuidas välditakse nende sattumist vale inimese kätte või automaati sissemurdmist? Kuidas kontrollitakse automaadis ravimite säilitustemperatuuri, kõlblikkusaega, pakendi puutumatust ja ehtsust? Kuidas kõrvaldatakse automaadist ravim, mille puhul ilmneb kvaliteediprobleem või mis tuleb kiiresti müügilt tagasi kutsuda? Mis juhtub interneti-, elektri- või tarkvaratõrke korral? Kas süsteem on ehitatud nii, et vähimagi kontrollimata olukorra korral ravimit ei väljastata? Kuidas lahendatakse olukord, kus makse on tehtud, kuid tehnilise rikke tõttu ravimit ei väljastata või automaat väljastab vale pakendi? Kuidas peab automaadi asukoht tagama, et kõrvalised inimesed ei kuuleks patsiendi tervisemuret ega näeks tema retsepte? Milliseid kontrolle teeb Ravimiamet enne automaadile tegevusloa andmist ning kuidas toimub hilisem järelevalve? Kas Ravimiamet saab vajaduse korral nõuda mõne ravimi eemaldamist automaadist või automaadi töö viivitamatut peatamist? Millised Rapla 2023. aasta Benu aparaadi pilootkatse tulemused või probleemid on praeguste nõuete koostamisel arvesse võetud? Palun vastake esimesel võimalusel. Parimat Angelina Lon Geeniuse ajakirjanik Delfi Meedia AS angelina.lon@geenius.ee | +372 58705026 ------=_NextPart_001_059A_01DD5642.686FCA90 Content-Type: text/html; charset="utf-8" Content-Transfer-Encoding: quoted-printable

 

Saatja: Angelina Lon <angelina.lon@geenius.ee>Saadetud: esmasp=C3=A4ev, 28. september 2026 = 15:42
Adressaat: Kommunikatsioon - RA <press@ravimiamet.ee>
Tee= ma: Apteegiaparaadid

 

T=C3=A4helepanu! Tegemist on v=C3=A4lisv=C3=B5rgust = saabunud kirjaga.
Tundmatu saatja korral palume linke ja faile mitte = avada.

Tere!

 

Kirjutan Geeniuses lugu apteegiautomaatidest, mida = riik kavandab. Soovin t=C3=A4psustada, kuidas hakatakse automaatides = tagama ravimiohutus, n=C3=B5ustamine ja s=C3=BCsteemi = t=C3=B6=C3=B6kindlus.

 

Palun vastake j=C3=A4rgmistele = k=C3=BCsimustele.

 

Kuidas n=C3=A4eks ravimi ostmine apteegiautomaadist = samm-sammult v=C3=A4lja? Millal peab inimene end tuvastama ja millal = =C3=BChendatakse ta proviisori v=C3=B5i = farmatseudiga?

 

Kas inimese tuvastamine ja videon=C3=B5ustamine on = kohustuslik ka tavalise k=C3=A4sim=C3=BC=C3=BCgiravimi, n=C3=A4iteks = valuvaigisti v=C3=B5i nohurohu ostmisel?

 

Milliseid andmeid n=C3=A4eb apteeker automaati = kasutava inimese kohta? Kas apteeker n=C3=A4eb =C3=BCksnes valitud = retsepti v=C3=B5i ka inimese teisi retsepte ja varasemaid = ravimioste?

 

Kas =C3=BCks apteeker v=C3=B5ib samal ajal = teenindada mitut eri kohtades asuvat automaati? Kas kehtestatakse = maksimaalne automaatide v=C3=B5i klientide arv, mida =C3=BCks apteeker = korraga teenindada v=C3=B5ib?

 

Kas automaadist v=C3=B5ib kavandatavate reeglite = j=C3=A4rgi v=C3=A4ljastada narkootilisi ja ps=C3=BChhotroopseid = ravimeid? Kui jah, siis kuidas v=C3=A4lditakse nende sattumist vale = inimese k=C3=A4tte v=C3=B5i automaati = sissemurdmist?

 

Kuidas kontrollitakse automaadis ravimite = s=C3=A4ilitustemperatuuri, k=C3=B5lblikkusaega, pakendi puutumatust ja = ehtsust?

 

Kuidas k=C3=B5rvaldatakse automaadist ravim, mille = puhul ilmneb kvaliteediprobleem v=C3=B5i mis tuleb kiiresti = m=C3=BC=C3=BCgilt tagasi kutsuda?

 

Mis juhtub interneti-, elektri- v=C3=B5i = tarkvarat=C3=B5rke korral? Kas s=C3=BCsteem on ehitatud nii, et = v=C3=A4himagi kontrollimata olukorra korral ravimit ei = v=C3=A4ljastata?

 

Kuidas lahendatakse olukord, kus makse on tehtud, = kuid tehnilise rikke t=C3=B5ttu ravimit ei v=C3=A4ljastata v=C3=B5i = automaat v=C3=A4ljastab vale pakendi?

 

Kuidas peab automaadi asukoht tagama, et = k=C3=B5rvalised inimesed ei kuuleks patsiendi tervisemuret ega = n=C3=A4eks tema retsepte?

 

Milliseid kontrolle teeb Ravimiamet enne automaadile = tegevusloa andmist ning kuidas toimub hilisem = j=C3=A4relevalve?

 

Kas Ravimiamet saab vajaduse korral n=C3=B5uda = m=C3=B5ne ravimi eemaldamist automaadist v=C3=B5i automaadi = t=C3=B6=C3=B6 viivitamatut peatamist?

 

Millised Rapla 2023. aasta  Benu aparaadi = pilootkatse tulemused v=C3=B5i probleemid on praeguste n=C3=B5uete = koostamisel arvesse v=C3=B5etud?

 

Palun vastake esimesel = v=C3=B5imalusel.

 

Parimat

Angelina = Lon

Geeniuse = ajakirjanik

Delfi Meedia AS

angelina.lon@geenius.ee | = +372 58705026

 

 

------=_NextPart_001_059A_01DD5642.686FCA90-- ------=_NextPart_000_0599_01DD5642.686FA380 Content-Type: image/png; name="image.png" Content-Transfer-Encoding: base64 Content-ID: iVBORw0KGgoAAAANSUhEUgAAANEAAAAxCAYAAABEfkxtAAAAAXNSR0IArs4c6QAAAARnQU1BAACx jwv8YQUAAAAJcEhZcwAADsMAAA7DAcdvqGQAABZqSURBVHhe7Z13WBTX+se/C9IUcEGkCCqLKAii scYCCtgVxWiMRmNBxYq9JN7k2nsHIRqxYuUaTRSwgYqggqCoRBQEUSlKU4rswhLK/QN2dufM7M4i /n43+sznefZ59nzPmdk275z3vOc9ZwU1NTU14OHh+Wg0SIGHh6d+8EbE80k4efw4hg4ajA727eHc qxeWLl6MosJCstkXiYB353gayrIlS/Dn+T9IGaZmZvjjwp8wMzcnq74o+J6Ip0Fc+ONPVgMCgLzc XPy4fDkpf3HwRsTTIKJu3SIlGnfv3EV5eTkpf1HwRsTTIN69KyAlGtXV1SgoUN3mc4c3Ip4GYWff npRo6OrqwsrKipS/KHgj4mkQk6ZMRpMmTUiZwmfhAlL64uCNiKdBWFlZ4eCRIzAxMSGrMNfHB7Pn zCHlLw4+xM3zSSguLkbIhQuIjYmFtUgEj5EjYG9vTzb7IqmXEUmrq3G/sAQ2TfRgoatDVtOorqyG +HURpAVi6DbXh76NEdmETnkOasQvgcatINCzJGt5eP6xqGVEWWXlWJOUhkMvsyhtgFkz/GhvgwGm zWhtAeDlycf4a/MtVJVVUpp5fxt03ToY2kZ6tLaoeIeqv/6FmjcX5ZqGFjS7BUJgNlixZb0pk0iQ kZEJqVSKFpYtWF2OhlBSUoLcnByIxWKYm1vA3OLTTSpmZmQgPz8fRsbGEIlEZPX/CZkZGSguLoZt 27bQ1dUlq7843rx5g9ycHDRv3hxWLVuS1WrDaURlVdVofzUar8VlZBUA4JJLVww1b06VXxxNQOL6 SFobGYbtTOB2cSI0tDRrheq/UXV7GGqKn5BNAQCaXX6FwPIbUlZKXm4ujgcdx63ISGRlZqKkpIRW r6OjAysrKzTjMCZpeTly83IRduUKmjZtSqvLysrCf84E41JYKF69fEWr09HRQfce3TFsuAe+Gz+O VseFVCrFH+fOIzQkBLExMWQ1HBwd4eziDO+Zs2BkzOzVJ4wbj7h790iZgaWlJW7duU2VX6SlYf++ fbgRcR3FxcWU3qJFC7i5u2Px0iUQGjFfb82q1TgRFETKrCQmJSE/Px/9XV3JKlYWL12KefN9qHLP bt3VCpO79O2LI0HHSJmi8H0hDh08iOsREUh9/pyshoWFBaxFIvRzdcXwER6wsLAgm7DCaUTrn6Zh VVIaKVOY6mgjd6Q7AEBaIMEVl0BUV1SRzSg6bxwI6/FOAIDq5C2oTvUlm8jR0Eaj4a9JlZVf/f2x a8dOmmZnb4cjQUEwNTXFnJmzEH7tGq1eFSM9PbHLdw9N2+vrB9/du6myg6Mjlq1YDh0dHRw/FoQr ly9Tde0dHOAX4K9WL3IrMhKrfv4F2dnZlDZx0iT0H9Afaamp2LRhI6U3bdoU6zZuwHAPD0oDgPi4 eNyKjMSxo0dRJpHQ6hSRGVF5eTnWr12L4NNnyCY0TM3McOL0KdjY2ND0lOQUnD93DocCA2k6G4lJ SdDQ1EDIhQu4dvUabt64QTahQRrRjYjriIqK4jRaVUa019cPB/bvR1lZbWcw3MMD07xnoFOnTgCA sNBQ+O7ajfT0dOqYo8eD4OziQpWVwWlE1mG38FrC3gvJSB/WD6Imesi5mY6YGX+S1TQsh7ZDD//a C6Dyageg4h3ZhIamyxUIhLUflI2CggLMnTUbCQ8ekFWIvB1NzVFIpVL0d3VFztscshmaNWuGNra2 NG3JsmXo1r0bACAvLw/e06Yj6Ym8x3Rzd0fg4UMKRwA/LV+B38+epcpCIyMcOx4Exw4daO0U2bhu PY4cPkyV9fT0cOzEcXTp2pXSoqOi4DV5ClUGgJ///Qu8pk+naQCw0Gc+wkJDSZnC0tISF8JCMWHc ODxPYd6N2bCyssLl8GvQ0yNccQALfHxwKTSMlGkkJiWhcZPGAIAPHz6gs1NHsgkN0ohkjBg6DM+e PSNlCjYjkoglmO7lhfi4OEpr7+CAkEvs73nqpEm4HV3bU/8WGIj+AweQTRhwhrjflEtJicHzD2IA gDhD7g4oQ5IlbyPQaESrY0X8glRozJw+ndWABg8ZQpvk09HRwXfjxtPayCgtLcWPK3/CqeAz1ENm QC9evMAojxE0AwKA1WvX0MoAsGLlT7RyUWEhZnvPZLiVMmZ4TaMZEACM/vZbmgGh7uLoR7hCG9dv YE25USfZc/2atRCJbLBg0UKMn/A9dYErIysrCwF7/UkZANCqZStSUomBgQH09fVJWS3U+Wwka1ev phkQALj3r/Wc2Ni6fTv1XFtHm1anDE4jstVX/QUDQA/j2nGDronySTcZuuYG8oJR7YWqCoGwMylR BJ8+g8THiaQMAIyLDgBc3dxICajrpX5Z+S9SRuH7Qkyf6oW8vDya3q17N9aBqLGxMdzc6T/Q27dv sWHtOpqGusznyJs3SRnjv2c39JGenqSEFUuXQSKmu246OqqjptnZ2Wht3RoB+/dhwaJF2LBpE86e O082YxB0jN1N1GXpnbjgeo/KqO9xL168wLnffydlleMrM3NzjB1XO57V1v5ERrTcTrVPP7GVBYy0 tQAA5u420Gmm2uhsJspdMw2rb2l1JALT/kAT5a9/7OgRUqJoZ9eOlFg1Gc+ePWP0aMuWLEFWZiZN AwCnjsrdy686M43+/LlzSEtNpcpng4OVZj63d3AgJUDJeQsKChjfgUAgoJVJ2js4YMGiRTTNzt6O c1JUIpYgJiaWlDlfj42POQYfcVxYCLtbG3z6DB4/ekTKFIMGDwIAaGnVXtdccBqRl7UlhlrIo2+K WOjqYK1jW6qsqdcIXbYMgkCT/cOKJnaCqUtrqiwwHwJBi1G0NhSN9KFhv4JUKYoKC1X69EIhM6Kk q6vLiLYpcuf2Her5/fj7uBXJHmVUlQvWokULUgIAhIaEUM9379xFq5NBjssUaW0t/94UufDnBVJS SbNmzCkJAOjr2o+UGCjeCGRwDKn/p7x984aUKH6YMBF7ff3w4cMHsgpOHWvHbJ+sJwKAS85d0dnI kKY5GRrg6RAXtCHcPXN3GzifYPYwHX92xVfr+pMyNLvug8CE+AEbt0Yjt2gImiofgL57pzogUQP2 H9dQhRHl5sqDDv5+yqOGd+/egd+ePawPtnEKAMTcrQ1bnzl1muEeyqioqGCcT/HBRlpqKvLz80m5 3rSzsyMlBp/idf4/qaioICWKMokEvrt3w82lLw7s/41WZ2JigrRXL9HBqTaKzIVaRgQAbQlj6Wki hFCLPTCgLzImJZi5KXfLBE3od1mBYXtAV/Ug0siY+RqKSKXsARFVX2zz5rU9bklJCRWhYeN6eAT8 9viyPkIuKkwaKyCbl1AMg5NkZmQwzqf4UAZbD1FfhEIhKTGoqakmpX80Vi2VewwyioqKsG3LFrj0 6s06flIHtY1oTptWMKwzGlv9xljl0IZsQqHbvAk6rpIP4p1W9oO+iOleyRC0/gHQqushdM2gYf8j 2YSBsbEx6+BehrL1/bk5zBC3DKe60Gt0VBRZReNI0DGkvXpZr0dC4mNIxBLcjo4mT0fx3fhxjOPU efTq3Zs8FQ+Azl26kJJS3r59ix+XLceYUd8gOTmZrFaJ2kbk2twYBSP74+HA3kge4gIrPdVpIW2m dMbACC8MuDoVtjPoIVsSQVMnNBqcBM2+4WjUPx4CA/USF0ePGU1KFC/SmBPEKckppERhbmEO9wG1 7iYZzibJefuWlNQijeU9KcI2h8Xz8bi6ucFaZE3KKnn86BE8hgzF1StXyCqlqG1EAKClIcBXQkNo qhkl0RcZwcBWtdtFIdCEoGkHQEO9iAgALFi0SOlgPDqKece/cT2ClCj2+O2lnnP5/q9e0dN91EVV aBUNOC+PchTnferDvNlzOD0SGfUyIklFJvJL70AszSCrGJRIq3Ar4wMiX39AyjvuNfY1H8rxd2Qy qlLqdzf28/dnTSyNCA/HW6LHOHXiJK0sw8/fn5pcRd2YSBUJDxJISS0+cJw34/VrvH//npR5GkDX bt0QsH/fR03wbtm0iZRYUcuICiUPEZs+HVHPR+PBq0WITh2Da0l9kFfCjETVANh1Lxdmvo/heiIF bidTYP/bE4w8m4YCiTyrW0Z1diFK55/Ae5vlKBkbgCLnjXjXfD6k55lZCGzY2dvhSkQ4xn73HVmF 2d4zUfi+EFKpFDO8pjGMyszcHEEnT2CYx3CabsQSHlfkr8REKgerPjQVKo8Myoiti+LxfDoGDxmC yNvRmDyVnjrFRUpyisoAkwxOIyotT8f9Vz4oktAzA6prKpCQsQx5H+iGtDb6DZZez0R5JT2SE5Ja BLeTKaioooeeS8YGQHqGmX1cOusoyk8zJ/fYEAqF2LxtKy6GhWLAwIFUlC3pyRN079IFjnb2VHaA UCjEoMGDsX3nTkTcuI7effoQZwNM6o5XRnl5Oc4p5Mipi+x9qeLkiROkxPMJEAqFWLVmDcJv3qDG vurw5C/2jBhFOI3o1buTqKpWHhZOzJTnkGWUVGD9beUTXE/yy3DsL/m4oOxAJKpSc2ltFBEvYHe/ lOHg6AjPUaPQxtYWwzyG4+CRw9gfeAA/rlwJX/+9CLtyBfcfPcSvv+3HN2NGQ68xe3aFU0fu+YGD gQdJiRPbtm1ZkzgVuRcbq3I2vaHUd9afi099PgCorPyblD6Kvb5+tMx4ABCJRDhw8CBOBZ9RmRgs gysYBHWMKP+DaveisroUkora1Jir6cWoZp/jpLiaLh8XVATTEwPZqHyg/mB76eLFmD9vHmJjYuDn 7w9XNzcMGDgQ3rNmYriHB+zsuScUAaBv376kxCArMxOHD9bPkHR0dNDH2ZmUGWxYt56UPhmfOsPg Y87HlU5TkK86AKMuvrt348H9+6QMAOjx9de4EBqCvQEBrGNqGepkLXAa0d/VamRmV9T2PpK/uSfj MorlvVp1nuqBNgBUZ6jOTJAxb/YcXPhDvgzDe9p07P/1V9yIuI6M1+qtSZKh17gxPEcpSUdSYPfO XXiYoF6QYdeOnSgoKMCYscxsDpKHCQnYs4s9NYjkUmgYLoddImWlfOqe42POZ6wk9UhGVpZ8BXVD 4fp9hg4fhisR4UpTuaytlScJyOA0osZa3PsdCPVqu0VHE9WuCgA4mcrbaPVUPmErQ7Mrd5z/2tWr jLj+zRs3sGPbdsycMQPu/VzhaGeP0Z6eWLF0GQJ/O4DoqCjWrGQZi5cuISUGZWVl8Jo8RWmqj4yf V67E5bAwmJiYYOCgQazJpCT+fntpi/HYuB4egQU+PqwrXf/JtG+veq+66KgoxqR4WVkZkpOVryVS xo2I66TEQCgUYuHixaQMAJ9mPZFNcy9SomFlNAKNNGuXQPQXGaKzGTnOkN+ptDUFWNFTns6jPa4H 9ZwN7aFO0Gyl+q4FAE+TkkiJgVQqReLjRJw/dw5bN2+G1+QpcHJwxIRx43Hk0CHGj2bVsiV+WbWK prFRWlqKaVOmYtH8BYgID6fdRePj4jBpwkQEnz6DTVu3UvqGzZtgYKCwJEQJhw8ehMeQoThy6BDt M2ZnZ2PLpk2Y5e2NmbNnoWevXlRddbVqb6AhqTtsrltVlfJVzDLIPEY3Fet5ZCxasIC6yRUXF2Ph /PmM5fgkbO8vOzsbZ4ODSZkBW4a/s4sL2rThvtFzGlEL4VCYGTLX5gBAY20r2JrOpsoCAKdH2cDK QNGPrP1gWhoCHBpuDbtm8kwH7QGO0Bn/tUJbORrNDaD3E30JtDIKC4tISW3i7t3DxvUb0KdnL8yf N482TzN1mheWrVBvQ/bQkBDM9p4JV2cX2FqLYGstwvffjUPM3bvYsn0buvfoTrW1t7fH0RPH1Zq7 SE5Oxsb1GzByuAd13n59nHHwQCCcXZyx4if6QkCJpHaBpDLKytjn7NTZL5utDdfrgeW4wUOGwLat PPufjfi4ePTo2g2eHiPQtdNXkIglGDRY9cY1Uinz/QHAurXrOG+05IpZcwtzbN9F325AGZxGBACd W21HUz36OhdDXTs4t/0PdLVMabpdM11ET2IO4C+Pa4sfOjB7Ff29P0BrAP3cmjbNIYz5Nxo5sC8r IOFyD9TlctgleAwZihcv5KtpZ8+di607Pm7W28TEBAcOHcK3Y8eSVejUqRPO/fkHLC253WU2fly5 EkePHydl3I9nH0jLePbsKcRi5oWvziYnjx4+JCXEsqwxImEb3G/aspmUGJSVlSHpyRO0s2uHvQEB 0NBQfbkmJSXRPpvMzS2TSDB29BgcCgxkdeGzMjOxa/sOqmxqaooTp06rNSUBqLHHgoxHmSuRUyxP m2lpNAqOlj/T2sh4V1YFk930Lzx9rhNEQvaVieLlwSg/Kp/U0h7WEQbHvGltVCEWi9G3dx/abjUN oVOnTjh3gb5XROLjROzasUNlAqki07294bNgPqfbVlRYCD9fXwQdZd9gg2SYx3DM9fFhbIy4Yd06 REXeom20oQwLCwu0bNUK//rlZzQzMcGmDRvUDk60bdcOY779Fnl5ebh18ybthqOKocOHYfHSpbQN T549fYoVS5cxegFFevbqBf99v0IoFMJnzlyVWfCo+2wDBw/CqjVrIBaLcTwoCGdOnaYWV+o1bgwP Dw9YtLCARCJB0pMkxNy9Sx0/YuRIrF63Vq2sdhlqG9F78QMkvF6KymoxGmu3RA/RfkYvpEjgo3zM vFQbFQsY3ApzuypvW5mYiZIx/qgpkkDDzBCGZ32g2V697YpkpCSnYMWyZZzJo+oSfvMG6049SU+e 4M7tO3iYkIDXr18hLzcP5eXlsLOzQxtbW3Tp2hVDhg2t14+Auny96+ERePzoEZ6npCAnNxe5OTmw Flmjja0tHBwcMHbcOKWL/s79/juy6xnV+mb0aGhpaeM/wap3/CExNTWDjo4OMjO5078UGeHpyfqd hoaEIPRiCJKTk/GuoAAdnDqgW/ceGOk5Em3byccql0LDkJbGvexDU7MRY6OT+Lh43I+Pw8OEBGRk ZCI3JweVVVUQiURo2bIlbNq0wajR36g1BiJR24gAoKamEh+k6TDQsYVAoLprBYA3pX+jqroGLQ25 Y+2oqkbl0zdoZGcBaNftS8dBcXExTp86hUuhYXialIQmTZpghOdIvMl+g/j4eNauW1127t4Nz2+4 w9w8PPUyon8Sv+3bjwD/vdRGHW7u7ti5ZzcMDeUrcB8/eoTYmFjci42tt1H9e/VqTPGaSso8PAw+ SyM6eCCQkWGrzP1S5NHDh4i7F4eYu3c509wDDx9i7NzDw8PGZ2lEbNvKpr16SStzUVpaipCLF7Fz 23YUFdFD5Hp6eoi6c+ezm8Tk+d/APbD5B1JZyVxSUVpaSkoq0dfXx/cTJmDzNvkkqIzZc+fyBsSj Np+lEfXsLZ+hl0Gm/agLuc9bP1dXRmSHh0cVn6UR/bRyJeMvDnds3ca5jRYbipuku/d3x96AAFo9 Dw8Xn+WYCHUbkcz2nomXL+VjIQMDA0zxmoofJk9Wmd4OAI8fP8aBfftxte7vU+YvXIip01TnCfLw sPHZGpEMvz17cCLoOGNvgt59+sCxgyOsrUUwtzBHeno6Up8/R0pyCrXorVXr1hg9ZgwmT51CC43z 8NSHz96IZKQ+f464uDgkPHiA1OepyM3Jobl3hoaGMLcwh41NG3zVuTO+7tlTrRWsPDxcfDFGxMPz v+KzDCzw8PyT+C+3QnQkbqznxgAAAABJRU5ErkJggg== ------=_NextPart_000_0599_01DD5642.686FA380--